Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

27 Feb 2020 10:38

RNS Number : 3542E
Horizon Discovery Group plc
27 February 2020
 

 

Horizon Discovery Group plc

 

Director/PDMR Shareholding - Grant of Share Options

 

Cambridge, UK, 27 February 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Company"), a cell engineering company focused on commercializing the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, announces that the following options were granted over the Company's ordinary shares of 1 pence each ("Ordinary Shares") on 26 February 2020 to Terry Pizzie, CEO, and Jayesh Pankhania, CFO, in accordance with the Company's Long Term Incentive Plan:

 

Director

Number of Ordinary Shares over which options granted

Exercise price per share

Normal Vesting date

Terry Pizzie

42,931

£0.01

26 February 2022

Terry Pizzie

42,932

£0.01

26 February 2023

Terry Pizzie

624,594

£1.64

26 February 2023

Jayesh Pankhania

28,856

£0.01

26 February 2022

Jayesh Pankhania

28,856

£0.01

26 February 2023

Jayesh Pankhania

419,817

£1.64

26 February 2023

The options granted are equivalent to 0.79% of the Company's existing issued share capital. 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Terry Pizzie

2

Reason for the notification

a)

Position/status

Chief Executive Officer - Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Horizon Discovery Group plc

b)

Legal Entity Identifier

213800L812B9NI5M3G89

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 Identification code

Options over ordinary shares of 1.0 pence each

 GB00BK8FL363

b)

Nature of the transaction

Grant of options to acquire ordinary shares under the Company's Long Term Incentive Plan

c)

Currency

GBP

d)

Price(s) and volume(s)

Price

Volume

1p

85,863

164p

624,594

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

N/A

f)

Date of the transaction

26 February 2020

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Jayesh Pankhania

2

Reason for the notification

a)

Position/status

Chief Financial Officer - Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Horizon Discovery Group plc

b)

Legal Entity Identifier

213800L812B9NI5M3G89

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 Identification code

Options over ordinary shares of 1.0 pence each

 GB00BK8FL363

b)

Nature of the transaction

Grant of options to acquire ordinary shares under the Company's Long Term Incentive Plan

c)

Currency

GBP

d)

Price(s) and volume(s)

Price

Volume

1p

57,712

164p

419,817

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

N/A

f)

Date of the transaction

26 February 2020

g)

Place of the transaction

London Stock Exchange, AIM

 

Ends

 

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Jon Davies, Head of Investor Relations

Tel: +44 (0) 1223 655 580

 

Numis Securities Limited (Broker and NOMAD)

Freddie Barnfield / Duncan Monteith

Tel: +44 (0) 207 260 1000

 

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email: horizon@consilium-comms.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBDLFLBLLXBBQ
Date   Source Headline
25th Mar 20157:00 amRNSHorizon Discovery awarded AMSCI grant
24th Mar 20157:00 amRNSNotice of Preliminary Results
23rd Mar 20157:00 amRNSHorizon Discovery and ArcherDX Sign OEM Agreement
18th Mar 201510:39 amRNSAdditional Listing
11th Mar 20157:00 amRNSHorizon Provides Genomic Standards To CRUK
18th Feb 20157:00 amRNSInnovate UK funding award
11th Feb 20154:27 pmRNSAdditional Listing
5th Feb 201512:21 pmRNSAdditional Listing
2nd Feb 20157:00 amRNSHorizon Discovery Selected as Core Facility
27th Jan 201512:00 pmRNSAdditional Listing
23rd Jan 20154:46 pmRNSHolding(s) in Company
19th Jan 20157:00 amRNSRevenues expected to be ahead of consensus by 7%
15th Jan 20157:00 amRNSHolding(s) in Company
8th Jan 20157:00 amRNSAcquisition of Haplogen Genomics GmbH
30th Dec 20147:00 amRNSHorizon Discovery Group Signs Agreement for $810K
22nd Dec 20144:49 pmRNSAdditional Listing
19th Dec 20146:23 pmRNSHolding(s) in Company
8th Dec 20147:00 amRNSLaunch of Gene-Engineered Bioproduction Cell Line
26th Nov 20143:09 pmRNSHolding(s) in Company
24th Nov 20147:00 amRNSHorizon Enter Agreement with Adarza BioSystems
19th Nov 201412:26 pmRNSHolding(s) in Company
17th Nov 20147:00 amRNS$750,000 contract win from top ten pharma
3rd Nov 20147:00 amRNSAppoints Dr David Smoller as an Executive Director
15th Oct 20147:00 amRNSHorizon CombinatoRx Wins Contract
6th Oct 20143:14 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Oct 20147:00 amRNSCo-Exclusive Commercial Agreement Signed
29th Sep 20147:00 amRNSAcquires Sage Labs Inc. for $48M (£29M)
25th Sep 201412:30 pmRNSAdditional Listing
25th Sep 20147:00 amRNS$1.2 million Master Services Agreement
23rd Sep 20147:00 amRNSInterim Results for Six Months Ended 30 June 2014
17th Sep 20144:34 pmRNSHolding(s) in Company
15th Sep 20145:29 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
5th Sep 201410:17 amRNSAdditional Listing
3rd Sep 20147:00 amRNSNotice of Interim Results
5th Aug 20147:00 amRNSCRISPR Experts Join Scientific Advisory Board
28th Jul 20143:57 pmRNSAdditional Listing
25th Jul 20147:00 amRNSHZD sign Collaboration Agreement with Otsuka
23rd Jul 20147:00 amRNSTrading Update
3rd Jul 20147:00 amRNSLicenses AAV Gene Delivery Technology
19th Jun 201410:48 amRNSDirector/PDMR Shareholding
17th Jun 20143:35 pmRNSAdditional Listing
16th Jun 20147:00 amRNSTSB Grant for next generation cancer diagnostics
12th Jun 20147:00 amRNSLicenses CRISPR Technology from Broad Institute
11th Jun 201412:11 pmRNSDirector/PDMR Shareholding
9th Jun 20147:00 amRNSAppointment of two Non-Executive Directors
2nd Jun 20147:00 amRNSCompletion of Acquisition of CombinatoRx
15th May 20147:00 amRNSAcquisition
8th May 20147:00 amRNSHolding in Company
8th May 20147:00 amRNSLicenses Gene Editing Technology from ERS Genomics
6th May 20145:48 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.